American Society of Hematology

SHERPA: Blue

People

  1. Giralt
    Giralt
  2. Zelenetz
    Zelenetz
  3. Levine
    Levine
  4. Perales
    Perales
  5. Tallman
    Tallman
  6. O'Reilly
    O'Reilly
  7. Horwitz
    Horwitz
  8. Devlin
    Devlin
  9. Palomba
    Palomba
  10. Abdel-Wahab
    Abdel-Wahab

Groups

  1. Department of Medicine (3997)
  2. Hematologic Malignancies, Division of (3800)
  3. Center for Hematologic Malignancies (3677)
  4. GSK Faculty (1590)
  5. Adult Leukemia (1341)
  6. Sloan Kettering Institute Faculty (1075)
  7. Bone Marrow Transplant (986)
  8. Center for Molecular Imaging and Biotechnology (CMIB) (955)
  9. Lymphoma (940)
  10. Tow Center for Developmental Oncology (TCDO) (882)
Search Within
Formats
  1. Meeting Abstract (4150)
  2. Journal Article (1255)
  3. Research Letter (46)
  4. Review (44)
  5. Editorial (35)
  6. Guidelines (13)
  7. Correspondence (7)
  8. Miscellaneous (3)
Groups
  1. Department of Medicine (3997)
  2. Hematologic Malignancies, Division of (3800)
  3. Center for Hematologic Malignancies (3677)
  4. GSK Faculty (1590)
  5. Adult Leukemia (1341)
  6. Sloan Kettering Institute Faculty (1075)

More Groups

People
  1. Sergio Giralt (348)
  2. Andrew Zelenetz (341)
  3. Ross Levine (316)
  4. Miguel-Angel Perales (311)
  5. Martin Tallman (301)
  6. Richard O'Reilly (281)

More People

Years
  1. 2025 (62)
  2. 2024 (428)
  3. 2023 (478)
  4. 2022 (369)
  5. 2021 (284)
  6. 2020 (261)

More Years

Publications
  1. Blood (5172)
  2. Blood Advances (331)
  3. Hematology-American Society of Hematology Education Program (50)

Results (5553)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Cancer cachexia and weight loss before CAR T-cell therapy for lymphoma are independently associated with poor outcomes
    Journal Article

    Valtis, Y. K.; Devlin, S.; Shouval, R.; Rejeski, K.; Corona, M.; De Abia, A. L.; Rivas-Delgado, A.; Luttwak, E.; Cassanello, G.; Landego, I.; more...
    Blood Advances (2025)

    Fulltext@MSK | Save
  • Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: A secondary SWOG analysis
    Journal Article

    Banerjee, R.; Sexton, R.; Cowan, A. J.; Rosenberg, A. S.; Ailawadhi, S.; Rajkumar, S. V.; Kumar, S.; Dispenzieri, A.; Lonial, S.; Durie, B. G. M.; more...
    Blood (2025)

    Fulltext@MSK | Save
  • A phase 1 study of avapritinib in combination with decitabine in patients with systemic mastocytosis with an associated hematologic neoplasm
    Meeting Abstract

    Kuykendall, A. T.; Ball, S.; Gotlib, J.; Yi, C. Y. A.; Tashi, T.; Rampal, R.; DeAngelo, D. J.; Volpe, V. O.; Pettit, K. M.; Hoehn, G.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • CTEP 10590, NORM: Nodular lymphocyte predominant Hodgkin lymphoma patients treated in a randomized phase II trial with either rituximab or mosunetuzumab
    Meeting Abstract

    Steiner, R.; Bock, A. M.; Herrera, A. F.; Zulfa, O.; Hoffmann, M.; Ibrahimi, S.; Galanina, N.; Lee, H. J.; Green, M.; Lin, R.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Phase 3, randomized, open-label study of epcoritamab plus lenalidomide compared with rituximab plus gemcitabine and oxaliplatin in patients with relapsed or refractory diffuse large B-cell lymphoma
    Meeting Abstract

    Ozcan, M.; Kim, W. S.; Zhang, H.; Bouzani, M.; Nagy, Z.; Chuah, H.; Salles, G.; Jeng, E. E.; Huang, J.; Sacchi, M.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Treatment outcomes of monoclonal gammopathy of renal significance with novel agents
    Meeting Abstract

    Dandwani, M.; Rashid, A.; Moore, D. C.; Balmaceda, J.; Abousaida, B.; Sannareddy, A.; Laverick, P.; Rastogi, P.; Thayyil, A.; Davis, J. A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Talquetamab in B cell maturation antigen (BCMA) exposed relapsed-refractory multiple myeloma patients
    Meeting Abstract

    Shaikh, H.; Lochner, J.; Loeffler, B.; Friend, R.; Habib, A.; McKenna, M.; Snyder, J.; Davis, J. A.; Patrus, G.; Dileo, R.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • A multi-site break through cancer trial: Phase II study investigating dual inhibition of BCL2 and menin in AML MRD using the combination of venetoclax and revumenib (trial in progress)
    Meeting Abstract

    Issa, G. C.; Ambinder, A. J.; Xiao, W.; Manalis, S.; Shalek, A. K.; Gondek, L. P.; Kentsis, A.; Short, N. J.; Daver, N.; Ning, J.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • CD38-SADA pretargeted radioimmunotherapy (PRIT) with Lutetium 177 (Lu177)-DOTA in adult patients with relapsed or refractory non-Hodgkin lymphoma: A first-in-human phase 1 trial
    Meeting Abstract

    Zain, J.; Wong, J.; Horwitz, S.; Pandit-Taskar, N.; Al-Janadi, A.; Mancini, B.; Khawaja, R.; Lee, C. Y.; Howansky, A.; Liles, D.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • OPTIMIZE: A phase II study of reduced dose post transplantation cyclophosphamide as GVHD prophylaxis in adult patients with hematologic malignancies receiving HLA-mismatched unrelated donor peripheral blood stem cell transplantation
    Meeting Abstract

    Auletta, J. J.; Devine, S. M.; Stefanski, H. E.; Spellman, S. R.; Defor, T. E.; Logan, B. R.; Butler, B. J.; Gooptu, M.; Shaffer, B. C.; Jimenez, A. M. J.; more...
    Blood (2024)

    Fulltext@MSK | Save